BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Post A, Groothof D, Eisenga MF, Bakker SJL. Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both? J Clin Med 2020;9:E1603. [PMID: 32466262 DOI: 10.3390/jcm9051603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Groothof D, Post A, Bakker SJ. Letter by Groothof et al Regarding Article, “Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial”. Circulation 2022;146. [DOI: 10.1161/circulationaha.122.060263] [Reference Citation Analysis]
2 Groothof D, Post A, Polinder-Bos HA, Erler NS, Flores-Guerrero JL, Kootstra-Ros JE, Pol RA, de Borst MH, Gansevoort RT, Gans ROB, Kremer D, Kieneker LM, Bano A, Muka T, Franco OH, Bakker SJL. Muscle mass and estimates of renal function: a longitudinal cohort study. J Cachexia Sarcopenia Muscle 2022. [PMID: 35596604 DOI: 10.1002/jcsm.12969] [Reference Citation Analysis]
3 Choosongsang P, Soonthornpun S. Overestimation of glomerular filtration rate calculated from creatinine as compared with cystatin C in patients with type 2 diabetes receiving sodium-glucose cotransportor 2 inhibitors. Diabet Med 2021;:e14659. [PMID: 34309941 DOI: 10.1111/dme.14659] [Reference Citation Analysis]
4 Fernandez-Fernandez B, D'Marco L, Górriz JL, Jacobs-Cachá C, Kanbay M, Luis-Lima S, Porrini E, Sarafidis P, Soler MJ, Ortiz A. Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. J Clin Med 2020;9:E2030. [PMID: 32605278 DOI: 10.3390/jcm9072030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]